Related Experiment Videos
Anguidine: a broad phase II study of the Southeastern Cancer Study Group
Cancer Treatment Reports
|February 1, 1984
Summary
Anguidine showed limited efficacy in treating solid tumors, with only minor responses observed in a phase II trial. While hematologic toxicity was noted, it was manageable, suggesting potential for further investigation in specific patient populations.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Anguidine is an investigational agent evaluated for its anti-cancer properties.
- Solid tumors represent a diverse group of malignancies requiring novel therapeutic strategies.
Purpose of the Study:
- To assess the efficacy and safety of anguidine in patients with advanced solid tumors.
- To determine response rates and toxicity profiles of anguidine therapy.
Main Methods:
- A phase II clinical trial was conducted involving 276 patients with solid tumors.
- Patients received anguidine treatment, and outcomes were evaluated based on response criteria and toxicity monitoring.
Main Results:
- The overall evaluability rate for the study was 68%.
- Hematologic toxicity was observed and considered substantial but not prohibitive.
- No complete responses were recorded; two partial responses and 12 stabilizations were achieved.
Conclusions:
- Anguidine demonstrated limited clinical activity in this phase II trial for solid tumors.
- The observed toxicity profile suggests careful patient selection and monitoring may be necessary for future studies.